Allogene Therapeutics Inc
For the period ended Mar 31, 2025. Filed May 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 13, 2025
ALLO$0.93-12.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(59,733) | $(65,000) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 12,175 | 11,924 |
| Depreciation and amortization | 3,099 | 3,555 |
| Net amortization/accretion on investment securities | (1,306) | (2,797) |
| Non-cash rent expense | 1,130 | 1,154 |
| Non-cash collaboration revenue - related party | — | (14) |
| Share of loss from equity method investments | — | 929 |
| Changes in operating assets and liabilities: | ||
| Deposit placed in escrow | (868) | — |
| Prepaid expenses and other current assets | (623) | (86) |
| Other long-term assets | 425 | 1,445 |
| Accounts payable | (336) | (118) |
| Accrued and other current liabilities | (5,223) | (5,690) |
| Operating lease liabilities | (1,833) | (1,209) |
| Other long-term liabilities | 164 | 8 |
| Net cash used in operating activities | (52,929) | (55,899) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (99) | (8) |
| Proceeds from maturities of investments | 56,500 | 103,272 |
| Purchase of investments | (50,225) | (81,131) |
| Net cash provided by investing activities | 6,176 | 22,133 |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock from ATM offering, net of commissions and issuance costs | 10,002 | — |
| Proceeds from CIRM award | 3,350 | — |
| Proceeds from issuance of common stock upon exercise of stock options | — | 794 |
| Proceeds from issuance of common stock under the employee stock purchase plan | 638 | 856 |
| Net cash provided by financing activities | 13,990 | 1,650 |
| Net change in cash and cash equivalents and restricted cash | (32,763) | (32,116) |
| Cash and cash equivalents and restricted cash — beginning of period | 85,510 | 93,447 |
| Cash and cash equivalents and restricted cash — end of period | $52,747 | $61,331 |
| Non-cash operating activities: | ||
| Right-of-use asset obtained in exchange for lease liability | $— | $2,409 |
| Non-cash deferred revenue and other long-term liabilities | $3,079 | $3,079 |
| Supplemental disclosure: | ||
| Cash paid for amounts included in the measurement of lease liabilities | $(3,227) | $(3,068) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.